Grifols will build new manufacturing site in Spain to double its plasma fractionation capacity in Europe

Barcelona, Spain, July 16, 2025 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced today that it will invest EUR 160 million in a new facility in Lliçà de Vall (Barcelona), expanding its industrial footprint in Spain and doubling its plasma fractionation capacity in Europe. With this new plant, the company will strengthen its ability to serve the more than 300,000 patients across the continent who rely on plasma-derived medicines, reinforcing its commitment to Catalonia, Spain and Europe.

Construction of the new plant will begin this year, with operations expected to start in 2030. It will join Grifols’ adjacent and historic production site in Parets del Vallès to form a 25-hectare biotechnology hub. The new manufacturing complex in Lliçà de Vall, which will span over 80,000 square meters, is expected to create more than 400 highly qualified jobs once operational. With this expansion, the company’s combined presence in Parets del Vallès and Lliçà de Vall will top 3,700 employees.

“Spain and Catalonia are strategic partners for our long-term growth and for jointly advancing scientific progress in healthcare, as well as the region’s industrial, environmental and social development. Expanding our production capacity will allow us to meet the growing European demand for plasma-derived medicines from our new facilities. In doing so, Grifols continues to fulfill its core mission: to care for the health and well-being of the more than 300,000 European patients who rely on our therapies,” said Nacho Abia, CEO of Grifols. He added: “We are especially pleased to expand our presence in the Vallès Oriental area, which we plan to call home for a long time to come.”

“We are proud and delighted to welcome Grifols to Lliçà de Vall, where we look forward to collaborating together to build a sustainable and lasting relationship for the mutual benefit of the people of Lliçà and Grifols,” said the mayor of Lliçà de Vall, Xavi Castillejo.

“Parets de Vallès, home to Grifols world-class manufacturing for more than 50 years, is delighted that the company will not only continue to be an integral part of Parets but also expand right next door, establishing a powerful biotechnology center of excellence,” said Francesc Juzgado, the mayor of Parets de Vallès.

A sustainable new plant to meet growing demand

The rising regional demand for immunoglobulins and other plasma-derived medicines is driving the expansion of the complex.

The new facilities will include a plasma fractionation plant, logistics operations, a testing laboratory and warehouses. There will also be a new space for Grifols Engineering, which as a world-renowned provider of first-class biopharmaceutical installations will design and construct the Lliçà de Vall expansion.

As a recognized global leader in sustainability, Grifols will incorporate advanced technologies throughout the Lliçà de Vall site. The company expects to power 100% of operations through renewable electricity, smart resource monitoring and management systems across a highly digitalized campus to minimize unnecessary consumption and ensure energy efficiency. Circular economy best practices will make certain that materials are reused, recycled, repaired and repurposed throughout their life cycles.

Grifols: 115 years of driving economic and social value

Since its founding in 1909, Grifols has made Spain and Catalonia cornerstones of its international growth – a commitment to patients and global society that has only deepened over more than 115 years of history.

The company’s sustained investment over the decades reflects its dedication to creating new opportunities, driving socioeconomic development and generating long-term value in the region.

In addition to its approximately 4,600 direct employees in Spain, Grifols generates more than 16,000 indirect jobs, contributing over EUR 1.5 billion to the Spanish economy – figures that are expected to grow as the Lliçà de Vall complex becomes operational.